BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38608703)

  • 1. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
    Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
    Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glycolytic metabolite that drives BRCA2 haploinsufficiency.
    Jiang P
    Cell; 2024 Apr; 187(9):2124-2126. PubMed ID: 38670069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation.
    Cassidy LD; Liau SS; Venkitaraman AR
    Mol Oncol; 2014 Mar; 8(2):161-8. PubMed ID: 24268522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.
    Skoulidis F; Cassidy LD; Pisupati V; Jonasson JG; Bjarnason H; Eyfjord JE; Karreth FA; Lim M; Barber LM; Clatworthy SA; Davies SE; Olive KP; Tuveson DA; Venkitaraman AR
    Cancer Cell; 2010 Nov; 18(5):499-509. PubMed ID: 21056012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
    Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
    Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.
    Rowley M; Ohashi A; Mondal G; Mills L; Yang L; Zhang L; Sundsbak R; Shapiro V; Muders MH; Smyrk T; Couch FJ
    Gastroenterology; 2011 Apr; 140(4):1303-1313.e1-3. PubMed ID: 21199651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.
    Abaji C; Cousineau I; Belmaaza A
    Cancer Res; 2005 May; 65(10):4117-25. PubMed ID: 15899802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of
    Karaayvaz-Yildirim M; Silberman RE; Langenbucher A; Saladi SV; Ross KN; Zarcaro E; Desmond A; Yildirim M; Vivekanandan V; Ravichandran H; Mylavagnanam R; Specht MC; Ramaswamy S; Lawrence M; Amon A; Ellisen LW
    Sci Adv; 2020 Jan; 6(5):eaay2611. PubMed ID: 32064343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic pathways in hereditary and sporadic breast cancer.
    Kenemans P; Verstraeten RA; Verheijen RH
    Maturitas; 2004 Sep; 49(1):34-43. PubMed ID: 15351094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.
    Tan SLW; Chadha S; Liu Y; Gabasova E; Perera D; Ahmed K; Constantinou S; Renaudin X; Lee M; Aebersold R; Venkitaraman AR
    Cell; 2017 Jun; 169(6):1105-1118.e15. PubMed ID: 28575672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA2 and pancreatic cancer.
    Naderi A; Couch FJ
    Int J Gastrointest Cancer; 2002; 31(1-3):99-106. PubMed ID: 12622420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of PALB2-associated breast cancers.
    Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
    J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
    Hattori H; Skoulidis F; Russell P; Venkitaraman AR
    Mol Cancer Ther; 2011 Apr; 10(4):670-8. PubMed ID: 21289082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutational signature in gastric cancer suggests therapeutic strategies.
    Alexandrov LB; Nik-Zainal S; Siu HC; Leung SY; Stratton MR
    Nat Commun; 2015 Oct; 6():8683. PubMed ID: 26511885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
    Venkitaraman AR
    DNA Repair (Amst); 2019 Sep; 81():102668. PubMed ID: 31337537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    Davies H; Glodzik D; Morganella S; Yates LR; Staaf J; Zou X; Ramakrishna M; Martin S; Boyault S; Sieuwerts AM; Simpson PT; King TA; Raine K; Eyfjord JE; Kong G; Borg Å; Birney E; Stunnenberg HG; van de Vijver MJ; Børresen-Dale AL; Martens JW; Span PN; Lakhani SR; Vincent-Salomon A; Sotiriou C; Tutt A; Thompson AM; Van Laere S; Richardson AL; Viari A; Campbell PJ; Stratton MR; Nik-Zainal S
    Nat Med; 2017 Apr; 23(4):517-525. PubMed ID: 28288110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
    Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
    Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
    Wang H; Zeng ZC; Bui TA; DiBiase SJ; Qin W; Xia F; Powell SN; Iliakis G
    Cancer Res; 2001 Jan; 61(1):270-7. PubMed ID: 11196174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
    Xia B; Sheng Q; Nakanishi K; Ohashi A; Wu J; Christ N; Liu X; Jasin M; Couch FJ; Livingston DM
    Mol Cell; 2006 Jun; 22(6):719-729. PubMed ID: 16793542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.